EUVIMEDEUVIMED entdecken
Crossref

Endolysosomal Sequestration Effects Controlled Release of BRAF Paradox Breaker Nanoparticles

Chen Chen iD, Ana Marie Perea Del Angel iD, Ramya Sridharan, Daniel A Heller iD

ACS Nano · 30.09.2025 · 19 (38) · 33879-33890

DOI: 10.1021/acsnano.5c09100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 15.09.2025. Verfasst von Chen Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Nanoparticles, Lysosomes, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: NCI NIH HHS, Emerson Collective, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRAF remains one of the most important therapeutic targets in cancer, but BRAF inhibitors can cause "paradoxical" pathway activation and drug resistance through RAF dimerization. A clinical "paradox breaker" inhibitor of BRAF monomers and dimers can potentially evade drug resistance. However, patients are required to receive a high oral daily drug dose to achieve the target therapeutic window. Co-administration of a cytochrome P450 blocker can improve drug exposure, but the combination can lead to drug-drug interactions. We investigated delivery via fucoidan-based nanocarriers to improve pharmacologic properties. We found that the nanoparticles extended BRAF inhibition in cancer cells due to sequestration into endolysosomes, followed by controlled release from a lysosomal depot. Following intraperitoneal administration, nanoparticles improved drug pharmacokinetics in vivo without inhibiting cytochrome P450 and also resulted in substantial improvements in antitumor efficacy. This work describes a general nanotherapeutic strategy to improve the pharmacologic properties of drugs via intracellular depot formation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafNanoparticlesLysosomesAntineoplastic AgentsEndosomesProtein Kinase InhibitorsHumansAnimalsMiceDelayed-Action PreparationsCell Line, TumorDrug CarriersDrug Liberation

Stichwörter der Autor:innen

drug depotkinase inhibitornanomedicineprecision medicinetargeted delivery

Substanzen

Proto-Oncogene Proteins B-rafDelayed-Action PreparationsBRAF protein, humanAntineoplastic AgentsDrug CarriersProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
  • Weill Cornell Medicine, Cornell University, New York, New York 10065, United States.
  • Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.

ORCID-Profile: Chen Chen, Ana Marie Perea Del Angel, Daniel A Heller

Förderung

  • NCI NIH HHS
  • Emerson Collective
  • National Cancer Institute
  • Pershing Square Sohn Cancer Research Alliance
  • Expect Miracles Foundation
  • American Cancer Society
  • Division of Chemical, Bioengineering, Environmental, and Transport Systems
  • Commonwealth Foundation for Cancer Research Foundation

Zitieren

APA

Chen, C., Perea Del Angel, A. M., Sridharan, R., & Heller, D. A. (2025). Endolysosomal Sequestration Effects Controlled Release of BRAF Paradox Breaker Nanoparticles. ACS Nano, 19(38), 33879-33890. https://doi.org/10.1021/acsnano.5c09100

Vancouver

Chen C, Perea Del Angel AM, Sridharan R, Heller DA. Endolysosomal Sequestration Effects Controlled Release of BRAF Paradox Breaker Nanoparticles. ACS Nano. 2025;19(38):33879-33890. doi:10.1021/acsnano.5c09100

BibTeX
@article{Chen2025,
  author = {Chen, Chen and Perea Del Angel, Ana Marie and Sridharan, Ramya and Heller, Daniel A},
  title = {Endolysosomal Sequestration Effects Controlled Release of BRAF Paradox Breaker Nanoparticles},
  journal = {ACS Nano},
  year = {2025},
  volume = {19},
  number = {38},
  pages = {33879--33890},
  doi = {10.1021/acsnano.5c09100}
}
Kostenlos starten →